Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma

BACKGROUND: A first-in-human, randomized pilot phase II clinical trial combining vaccines targeting overexpressed, non-mutated tumor blood vessel antigens (TBVA) and tyrosine kinase inhibitor dasatinib was conducted in human leukocyte antigen (HLA)-A2(+) patients with advanced melanoma. METHODS: Pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Storkus, Walter J, Maurer, Deena, Lin, Yan, Ding, Fei, Bose, Anamika, Lowe, Devin, Rose, Amy, DeMark, Melissa, Karapetyan, Lilit, Taylor, Jennifer L, Chelvanambi, Manoj, Fecek, Ronald J, Filderman, Jessica N, Looney, Timothy J, Miller, Lauren, Linch, Elizabeth, Lowman, Geoffrey M, Kalinski, Pawel, Butterfield, Lisa H, Tarhini, Ahmad, Tawbi, Hussein, Kirkwood, John M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593702/
https://www.ncbi.nlm.nih.gov/pubmed/34782430
http://dx.doi.org/10.1136/jitc-2021-003675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593702/
https://www.ncbi.nlm.nih.gov/pubmed/34782430
http://dx.doi.org/10.1136/jitc-2021-003675

Ejemplares similares